Plain language summary on subcutaneous administration of isatuximab in people with relapsed and/or refractory multiple myeloma Future Oncol
Prognostic impact of cytogenetic alterations in newly diagnosed acute myeloid leukemia treated with risk-adapted protocols MED CLIN-BARCELONA
Long-term results from the AGILE study of azacitidine plus ivosidenib vs placebo in newly diagnosed IDH1-mutated AML Blood Adv
Proteins of the cancer cell secretome induce the protumoral microenvironment of diffuse intrinsic pontine glioma NEURO-ONCOL ADV
Belantamab mafodotin plus bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma (DREAMM-7): updated overall survival analysis from a global, randomised, open-label, phase 3 trial Lancet Oncol
Talquetamab improves patient-reported symptoms and health-related quality of life in relapsed or refractory multiple myeloma: Results from the phase 1/2 MonumenTAL-1 study CANCER-AM CANCER SOC